Mycophenolate Mofetil Hexal

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Hexal, is an antimetabolite immunosuppressant presented as an oral tablet for systemic use. It is employed to prevent organ transplant rejection and to treat lupus nephritis by suppressing lymphocyte proliferation.

GNH USA supplies Mycophenolate Mofetil Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Mycophenolate Mofetil is used in immunosuppressive regimens targeting organ transplantation and autoimmune kidney disease.

- Kidney transplant: helps prevent graft rejection and preserve renal function. - Liver transplant: reduces incidence of acute rejection episodes. - Lupus nephritis: improves renal outcomes and reduces proteinuria.

Mycophenolate Mofetil may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, may lead to dehydration. - Headache: transient, often resolves with continued therapy. - Increased susceptibility to infections: higher incidence of viral, bacterial, or fungal infections.

Serious or Rare Side Effects: - Bone marrow suppression: leukopenia, anemia, or thrombocytopenia. - Severe infections: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Malignancy risk: increased incidence of post‑transplant lymphoproliferative disorders.

When prescribing Mycophenolate Mofetil, clinicians should observe several safety measures.

- Blood counts monitoring: perform regular complete blood counts to detect leukopenia or anemia. - Renal function monitoring: assess serum creatinine and eGFR periodically. - Infection risk counseling: advise patients to report signs of infection promptly. - Live vaccine avoidance: do not administer live attenuated vaccines during therapy. - Pregnancy considerations: discuss potential risks and recommend effective contraception. - Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Mycophenolate Mofetil can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression may lead to severe cytopenias. - Ribavirin: combined use increases risk of hematologic toxicity. - Live vaccines: heightened risk of vaccine‑derived infection.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise mycophenolate exposure. - CYP3A4 inducers (e.g., rifampin): may reduce drug levels and efficacy.